<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826940</url>
  </required_header>
  <id_info>
    <org_study_id>CRU2C-ICNAS-001</org_study_id>
    <secondary_id>FLAD Life Science 2020</secondary_id>
    <nct_id>NCT03826940</nct_id>
  </id_info>
  <brief_title>From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1</brief_title>
  <acronym>ASD/NF1inhib</acronym>
  <official_title>Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Coimbra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Coimbra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate synaptic physiology and behavioral inhibition in patients with&#xD;
      NF1 and ASD and to answer whether inhibitory deficits at these levels are modulated by&#xD;
      lovastatin.&#xD;
&#xD;
      Structure: (1) Visit 1: Baseline assessment- participant's characterization, baseline outcome&#xD;
      measures and additional evaluations, (2) 3 consecutive days of physiologically probing&#xD;
      drug/placebo intake, (3) Visit 2: Outcome measures and additional evaluations in the day&#xD;
      after the last drug/placebo intake, (4) Washout period of 4 to 6 weeks, (5) 3 consecutive&#xD;
      days of drug/placebo intake, (6) Visit 3: Outcome measures and additional evaluations in the&#xD;
      day after the last placebo/drug intake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The literature has shown synaptic inhibitory dysfunction in both ASD and NF1. Here the&#xD;
      investigators aim to test whether a mechanistic link can be established between that synaptic&#xD;
      inhibitory dysfunction, systems levels changes in oscillatory synchrony and regulation of&#xD;
      inhibition and treatment with Lovastatin in these two neurodevelopmental disorders. The&#xD;
      investigators will explore this link through the application of complementary quantitative&#xD;
      measures (putative biomarkers), such as magnetic resonance spectroscopy (MRS) transcranial&#xD;
      magnetic stimulation (TMS) and electroencephalogram (EEG) applied to the same group of adult&#xD;
      patients before and after the lovastatin or placebo intake during three days.&#xD;
&#xD;
      The intervention comprehends three sessions: the first two visits will occur in the same week&#xD;
      and the third visit will take place 4 to 6 weeks later. In the first visit (baseline&#xD;
      assessment), participants will perform neuropsychological, EEG, MRS and TMS assessment. In&#xD;
      the other two visits participants will repeat EEG, MRS and TMS assessments to study possible&#xD;
      post- intervention effects. Participants will intake 60mg of Lovastatin or Placebo during&#xD;
      three consecutive days before the second and the third visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurochemical response changes to GABAergic stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Comparing changes in brain excitation-inhibition measures (i.e., glutamate and GABA) when the GABAergic system is activated by oral dose of the Lovastatin 60mg during 3 days versus the placebo condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor evoked potentials changes under motor cortical stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Amplitudes (mV) will be measured during stimulation of the primary motor cortex using transcranial magnetic stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical excitability changes under motor cortical stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Periods (ms) will be measured during stimulation of the primary motor cortex using transcranial magnetic stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain oscillations changes under sensory stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Power (microV^2) will be recorded during sensory stimulation using high density electroencephalography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-related potentials changes under sensory stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Amplitude (microV) will be recorded during sensory stimulation using high density electroencephalography.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Neurofibromatosis 1</condition>
  <arm_group>
    <arm_group_label>NF1 - experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NF1 - control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASD - experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASD - control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin 60 MG</intervention_name>
    <description>60 MG Lovastatin per day for 3 consecutive days</description>
    <arm_group_label>ASD - experimental</arm_group_label>
    <arm_group_label>NF1 - experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>60 MG Placebo per day for 3 consecutive days</description>
    <arm_group_label>ASD - control</arm_group_label>
    <arm_group_label>NF1 - control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive diagnostic results for ASD in:&#xD;
&#xD;
        The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.&#xD;
&#xD;
          -  Positive diagnostic results for NF1:&#xD;
&#xD;
        Clinical diagnosis based on the well-established clinical criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Global Intelligence Quotient &lt; 80&#xD;
&#xD;
          -  Associated medical condition such as epilepsy, neurologic conditions, genetic&#xD;
             syndromes, or other usual comorbidity in ASD and NF1 populations&#xD;
&#xD;
          -  Medication capable of interfering with the intervention and/or study results&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Drug use and/or alcohol abuse&#xD;
&#xD;
          -  Contra-indications to MR and TMS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel S Castelo-Branco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICNAS - Institute of Nuclear Sciences Applied to Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICNAS</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-043</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <reference>
    <citation>Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast. 2011;2011:297153. doi: 10.1155/2011/297153. Epub 2011 Jun 23. Review.</citation>
    <PMID>21766041</PMID>
  </reference>
  <reference>
    <citation>Violante IR, Ribeiro MJ, Edden RA, Guimar√£es P, Bernardino I, Rebola J, Cunha G, Silva E, Castelo-Branco M. GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact. Brain. 2013 Mar;136(Pt 3):918-25. doi: 10.1093/brain/aws368. Epub 2013 Feb 11.</citation>
    <PMID>23404336</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Coimbra</investigator_affiliation>
    <investigator_full_name>Miguel Castelo-Branco</investigator_full_name>
    <investigator_title>Research Director of CIBIT-ICNAS</investigator_title>
  </responsible_party>
  <keyword>Inhibition</keyword>
  <keyword>GABA</keyword>
  <keyword>molecular imaging</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Neurofibromatosis 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

